{"adverse_reactions":["Sincerus Florida, LLC. Adverse reactions ghv"],"components":["Active, inactive X"],"effective_time":"20190509","id":"8878ee14-5817-5631-e053-2995a90ab73f","instructions_for_use":["Directions for use w"],"openfda":{},"package_label_principal_display_panel":["NDC 72934-1161-2 NIACINAMIDE USP 4% / TAZAROTENE 0.1%. Gel 30gm f"],"set_id":"8878ee14-5816-5631-e053-2995a90ab73f","spl_product_data_elements":["NIACINAMIDE 4% / TAZAROTENE 0.1% NIACINAMIDE 4% / TAZAROTENE 0.1% NIACINAMIDE NIACINAMIDE TAZAROTENE TAZAROTENE clear gel"],"version":"1"}